Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | TRPV6 | Q9H1D0 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | METAP1 | P53582 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132664 | 0.90 | ALDH1A1 (0.56) | ALDH1A1KDM4ETSHRMEN1KMT2A | |
| SCHEMBL63474 | 0.89 | ALDH1A1 (0.59) | ALDH1A1KDM4ETSHRPOLBMEN1 | |
| SCHEMBL6132488 | 0.85 | ALDH1A1 (0.55) | ALDH1A1KDM4ETSHRPOLBMEN1 | |
| SCHEMBL6132519 | 0.85 | ALDH1A1 (0.55) | ALDH1A1KDM4ETSHRPOLBMEN1 | |
| SCHEMBL64407 | 0.85 | ALDH1A1 (0.58) | ALDH1A1TSHRPOLBMEN1KMT2A | |
| SCHEMBL6132487 | 0.85 | ALDH1A1 (0.55) | ALDH1A1KDM4ETSHRPOLBMEN1 | |
| SCHEMBL6135228 | 0.85 | ALDH1A1 (0.67) | ALDH1A1TSHRPOLBMEN1KMT2A | |
| SCHEMBL63892 | 0.85 | ALDH1A1 (0.63) | ALDH1A1TSHRPOLBMEN1KMT2A | |
| SCHEMBL6134915 | 0.83 | ALDH1A1 (0.65) | ALDH1A1TSHRPOLBMEN1KMT2A | |
| SCHEMBL6132216 | 0.83 | MEN1 (0.70) | ALDH1A1TSHRPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
| EP-1259535-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060846-A1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | ALDH1A1 4718/4885KDM4E 4687/4885TSHR 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.